Boehringer Ingelheim Launches Next-Generation Poultry Vaccine

Hyderabad: Boehringer Ingelheim has launched a new, next-generation vaccine to combat Marek’s disease, a persistent threat to India’s poultry industry. The breakthrough vaccine is designed for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day-old chicks, offering enhanced protection against the virulent strains of Marek’s disease.

Marek’s disease has long been a significant challenge in India’s poultry sector, despite widespread vaccination efforts. Boehringer Ingelheim’s new vaccine utilizes an innovative controlled attenuation process, which optimizes safety and efficacy. The vaccine, based on a serotype-1 construct, is aimed at addressing gaps in current vaccination methods, offering early and long-lasting immunity for young chickens, which are most vulnerable to the disease.

Dr. Vinod Gopal, Country Head of Animal Health at Boehringer Ingelheim India, emphasized the financial impact of Marek’s disease on farmers, particularly in light of the country’s growing poultry industry. The new vaccine is expected to reduce disease outbreaks, improve flock health, and support food security by ensuring the productivity of poultry farms.